Aim: In this study, we discuss the efficacy and safety of autologous hematopoietic stem cell transplantation (AHSCT) for high-risk pediatric solid-tumor patients based on 1 2 years of experience. Patients and Methods: The data of patients aged < 18 years with pediatric malignancies who underwent AHSCT between January 2009 and July 2021 at the Pediatric Bone Marrow Transplant Unit were evaluated retrospectively. Results: Fifty-one patients (24 girls and 27 boys; median age, 7.8 years; range: 0.5–18 years) were enrolled in the study; 20, 15, 8, 4, 2, and 2 patients had diagnoses of neuroblastoma, Ewing’s sarcoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, germ cell tumor, and soft tissue sarcoma, respectively. The median neutrophil and platelet engraftment times were 11 (8–45) and 16 (4–62) days, respectively, and the median hospital stay was 38 (17–67) days. The median follow-up time was 2.83 (0.12–10.81) years and the overall survival (OS) rate was 51.3 ± 10.3% for all patients; the median follow-up times and survival rates for the Ewing’s sarcoma and neuroblastoma cases were 2.63 (0.12–10.55) years and 64.2 ± 14.9%, and 2.81 (0.31–7.91) years and 42.8 ± 12%, respectively. All four patients who received the conditioning regimen of carboplatin, etoposide, and melphalan (CEM) died; 6 of 16 neuroblastoma patients who received the busulfan and melphalan (Bu/Mel) regimen as a conditioning regimen died: the median follow-up period of the Bu/Mel neuroblastoma patients was 3.08 (0.32–7.91) years and the OS rate was 55.1 ± 13.8%. Conclusion: Although the number of patients in this study was limited, AHSCT resulted in better survival for Ewing’s sarcoma and neuroblastoma cases than reported for those who did not undergo AHSCT in our clinic.